Daiichi Sankyo initiates Phase 3 trial for Destiny-Breast11 neoadjuvant therapy
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
The campaign aims to increase awareness about Tuberculosis as a curable disease and promote early diagnosis.
Market demand for significant volumes and quality of biopharma products would drive continuous manufacturing technologies
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
Owkin builds best-in-class predictive biomedical AI models and robust data sets
The companies expect to manufacture over 80 million does of the Covid-19 vaccine in 2022
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
It is estimated that one-third of our country’s population has some form of these disorders
A first for the Asian market, addressing the health spends needs of over 200 million households.
Subscribe To Our Newsletter & Stay Updated